GLP-1 Drugs Don't Work the Same for Everyone — And That Changes Everything

GLP-1 Drugs Don't Work the Same for Everyone — And That Changes Everything

Everyone "knows" Ozempic causes dramatic weight loss. The headlines say it. The before-and-afters confirm it. The waiting lists prove it.

But here's the uncomfortable truth hiding inside the clinical trial data: a significant chunk of people who take GLP-1 drugs lose very little weight — or none at all. And researchers are only now beginning to understand why.

Important: I'm not a doctor. Everything I share here is based on published research and my personal interest in this space. Talk to your physician before making any changes to your health regimen.

---

The Bottom Line

• GLP-1 drugs like semaglutide and tirzepatide produce average results that look impressive — but averages hide enormous individual variation.
• In major trials, roughly 10–15% of participants lost less than 5% of their body weight, even on full doses.
• Genetics, gut hormone levels, baseline metabolic health, and diet quality all appear to influence how well someone responds.
• There is no reliable test yet that predicts who will be a "super-responder" versus a "non-responder" — but that science is actively developing.
• Actionable takeaway: If you or someone you know had a weak response to one GLP-1 drug, that doesn't mean all GLP-1s will fail. The drug, the dose, the combination with diet, and even the specific receptor targeted may all matter.

---

The Story We Keep Telling About GLP-1 Drugs

The dominant narrative goes something like this: GLP-1 receptor agonists are a breakthrough. Semaglutide helps people lose 15% of their body weight. Tirzepatide gets you to 20–22%. These are life-changing numbers. The drugs work.

And that narrative is not wrong, exactly. The average results from the STEP trials for semaglutide and the SURMOUNT trials for tirzepatide really are impressive. When you zoom out, these are among the most effective weight loss medications ever studied.

The problem is the word average.

When a trial reports "15% mean weight loss," that number is doing a lot of heavy lifting. It's smoothing over a distribution that looks less like a bell curve and more like a wide, messy spread. Some people lose 5%. Some lose 30%. A meaningful minority barely budge.

That spread — what researchers call heterogeneity of treatment effects — is the story nobody is telling loudly enough.

---

What the Data Actually Shows About Response Variation

The source paper driving this conversation digs into this exact question. Researchers looked at GLP-1 trial data and broke down who actually responded, and by how much.

Here's what stands out:

In the STEP 1 trial of semaglutide 2.4 mg, the average weight loss was about 14.9% of body weight. Impressive. But roughly 10–15% of participants lost less than 5% — the threshold generally considered clinically meaningful for obesity outcomes.

Some participants lost essentially nothing.

A Bayesian network meta-analysis published in 2026 comparing tirzepatide, semaglutide, and liraglutide found similar patterns. Tirzepatide had the highest average response, but even there, the response distribution showed real tails on both ends — super-responders and near-non-responders sitting in the same trial.

This isn't a flaw in the drugs. It's a biological reality that the average-focused reporting almost entirely obscures.

---

Why Do Results Vary So Much? The Real Reasons

This is where the science gets genuinely interesting — and where the "just take Ozempic and lose weight" story breaks down.

Your Genetics Play a Role

GLP-1 receptor agonists work by binding to GLP-1 receptors throughout your body — in the gut, the pancreas, and critically, in the brain. Specifically, the brainstem and hypothalamus, where satiety signals get processed.

Research on brainstem GLP-1 neurons published in 2026 shows these neurons are a key driver of the appetite suppression and sustained weight loss seen in animal models. But receptor expression and sensitivity vary between individuals. Some people appear to have more robust GLP-1 receptor signaling to start with. Some may have polymorphisms that blunt the drug's effect.

We don't yet have a simple genetic test for this. But the biology strongly suggests genetics matter.

Your Baseline Metabolic Health Matters

People with type 2 diabetes, metabolic syndrome, and higher baseline insulin resistance tend to respond differently than people who are metabolically healthy but carrying excess weight.

Part of this comes down to what the drug is actually doing in each body. In someone with impaired insulin secretion, the GLP-1 drug is doing metabolic work that produces measurable benefit. In someone whose insulin system works fine, the appetite suppression pathway becomes the dominant mechanism — and that pathway varies widely by person.

Diet Quality Changes What GLP-1 Drugs Can Do

This one surprises a lot of people. A 2026 review on dietary fiber and GLP-1 receptor agonists found that dietary fiber and GLP-1 drugs share overlapping mechanisms — both stimulate endogenous GLP-1 release and support gut hormone signaling.

People eating high-fiber diets may already have a degree of native GLP-1 tone that interacts with the drug differently. The review also suggests that fiber-rich diets could enhance the durability of GLP-1 drug effects over time.

Translation: the person eating mostly processed food and the person eating a high-fiber whole food diet may have very different responses to the same GLP-1 dose — not because one is more disciplined, but because their gut biology is genuinely different.

The Specific Drug and Receptor Target Matter

Not all GLP-1 drugs are the same. Liraglutide, semaglutide, and tirzepatide all hit the GLP-1 receptor — but tirzepatide also hits the GIP receptor. That second target appears to significantly shift the response distribution.

According to a 2026 analysis of the GIP receptor's clinical potential, the GIP receptor activates complementary fat-burning and satiety pathways. Some researchers believe the GIP component in tirzepatide is precisely why its response rates skew higher — and why even some semaglutide non-responders do well when switched.

There's also emerging preclinical work on GIPR and glucagon receptor co-agonism — adding a third target to the mix — that restores normal weight in obese rodent models even when GLP-1 alone was insufficient. The implication: where you land on the response curve may partly depend on which receptors your body responds to most.

---

The Contrarian Point Nobody Wants to Say Out Loud

Here it is: the GLP-1 drug conversation has been dominated by averages and success stories, when it should also be about predicting who benefits most — and what to do when you're not one of them.

We've built a cultural narrative around these drugs as near-universal solutions. That narrative helps people access treatment they genuinely need. But it also sets up a subset of patients for confusion, self-blame, and treatment failure when the scale barely moves.

A meaningful minority of GLP-1 users are going through this right now. They're on full doses. They're doing "everything right." And they're losing 3–4% of their body weight after six months instead of 15%. Their doctors may not have explained that this was a real possibility. The media certainly didn't.

The research is clear that this is a biological phenomenon, not a willpower problem. But without that framing, it's easy for people to internalize the "failure" personally.

---

What Predicts a Better Response?

Researchers are actively working on this. Here's what the current evidence suggests — though nothing is definitive yet.

Better response more likely if:

• Higher BMI at baseline (more weight to lose, more metabolic disruption to correct)
• Significant insulin resistance or type 2 diabetes (more metabolic machinery for the drug to work with)
• Low baseline endogenous GLP-1 levels (the drug fills a bigger gap)
• Consistent high-fiber diet paired with the medication

Weaker response more likely if:

• Metabolically healthy obesity (insulin-sensitive, normal glucose)
• Already high native GLP-1 signaling
• Genetic variants affecting GLP-1 receptor sensitivity (still being mapped)
• Low-fiber, high-processed-food diet (may blunt gut hormone interactions)

Again — this is early science. No clinician can run a panel today and tell you with certainty which camp you'll fall into. But the field is moving toward predictive biomarkers, and within a few years, that picture will likely be clearer.

---

What This Means If You're Already on a GLP-1 Drug

If you're on semaglutide or tirzepatide and your results feel underwhelming compared to what you've read:

First, give it enough time. Peak weight loss on semaglutide takes 12–16 weeks after reaching the full dose. Early sluggish response doesn't always predict final outcome.

Second, look at the drug, not just the dose. If you've been on semaglutide for 6+ months at full dose with less than 5% weight loss, a conversation with your doctor about tirzepatide may be worth having. The additional GIP receptor action affects a different set of pathways, and some people who respond poorly to GLP-1-only drugs do substantially better on the dual agonist.

Third, take the fiber research seriously. The 2026 dietary fiber review is one of the more actionable findings here. Pairing a GLP-1 drug with a genuinely high-fiber diet isn't just good nutrition hygiene — it may actively enhance how well the drug works for you.

Fourth, talk to your doctor about what "success" looks like for you specifically. Cardiovascular risk reduction, blood pressure improvement, liver health markers — these can all improve meaningfully even with modest weight loss. The drug may be working in ways the scale doesn't capture.

---

The Bigger Picture: Personalized GLP-1 Medicine Is Coming

The reason this heterogeneity research matters so much right now is that it's laying the groundwork for something genuinely useful: precision prescribing.

Right now, the approach to GLP-1 drugs is essentially "start everyone at the lowest dose, titrate up, and see what happens." That's not irrational — it's how you practice responsibly when predictive tools don't exist yet.

But the field is moving fast. Researchers are actively mapping the genetic, hormonal, and metabolic variables that predict response. Work on dual and triple agonists is expanding the drug toolkit. And the neuropsychiatric effects of GLP-1 drugs — including their impact on reward signaling, addiction pathways, and mood — are adding another dimension to who benefits most.

Within a few years, the conversation will likely shift from "should you take a GLP-1?" to "which GLP-1 pathway matches your biology?"

That's a much more useful question.

---

FAQ

Why do some people not lose weight on Ozempic? Several factors can blunt response to GLP-1 drugs like semaglutide: genetic variations in GLP-1 receptor sensitivity, high baseline endogenous GLP-1 levels, metabolically healthy obesity, and diet quality. Research suggests roughly 10–15% of people in major trials lose less than 5% of their body weight even at full doses.

Does tirzepatide work better than semaglutide for non-responders? Possibly. Tirzepatide adds a second receptor target (GIP receptor) that semaglutide doesn't hit. Some people who respond poorly to GLP-1-only drugs appear to do better with the dual agonist. This is an active area of research, and no head-to-head trial for "semaglutide non-responders" specifically has been completed yet. Talk to your doctor.

Can diet affect how well GLP-1 drugs work? Yes, according to emerging research. A 2026 review found that dietary fiber and GLP-1 drugs share overlapping mechanisms. High-fiber diets may enhance the drug's effectiveness and durability, while diets low in fiber and high in processed foods may blunt the response.

What does "heterogeneity of treatment effects" mean in plain English? It means the same drug produces very different outcomes in different people. When a study reports an "average" result, that number hides a wide range — some people far above average, some far below. Heterogeneity research tries to understand why some people respond well and others don't.

Is a weak GLP-1 response a failure? Not necessarily. Even modest weight loss (3–5%) can improve blood pressure, liver health, and cardiovascular risk markers. And the drug may be working in metabolic ways the scale doesn't reflect. That said, if weight is the primary goal and results are minimal after 6 months at full dose, it's a reasonable conversation to have with your doctor about alternatives.

---

The Bottom Line: Averages Are Not Your Biology

GLP-1 drugs are genuinely remarkable. The research supporting their effectiveness is real and robust.

But "the average person loses 15%" is not a promise. It's a central tendency pulled from a wide, uneven distribution. A real person isn't an average. They're one data point — shaped by their genetics, their gut hormones, their diet, and the specific receptor pathways their body responds to most.

The contrarian take here isn't "GLP-1 drugs are overhyped." It's "we've been talking about them as if they work the same way for everyone, and that framing is failing the people who respond differently."

If your results don't match the headlines, that's not a personal failure. It's biology. And the science is getting better — fast — at figuring out whose biology matches which drug.

That's worth paying attention to.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research — not medical recommendations.

---

Sources

1. Heterogeneity of Treatment Effects of GLP-1 Receptor Agonists for Weight Loss — PubMed, 2025
2. STEP 1 Trial: Semaglutide 2.4mg for Obesity — New England Journal of Medicine, 2021
3. SURMOUNT-1 Trial: Tirzepatide for Obesity — New England Journal of Medicine, 2022
4. Comparison of Tirzepatide, Semaglutide, and Liraglutide: Bayesian Network Meta-Analysis — Advances in Therapy, 2026
5. [Brainstem GLP-1 Neurons and Sustained Weight Loss in Obese Mice](https://pub